Point72 Asia (Singapore) Pte. Ltd. Bio Xcel Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 15,186 shares of BTAI stock, worth $5,315. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,186
Previous 30,295
49.87%
Holding current value
$5,315
Previous $38.8 Million
76.11%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BTAI
# of Institutions
54Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$420,4810.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$154,2390.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$104,3150.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$64,7700.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$45,4540.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $9.81M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...